Total revenue increased to $100.4 million from $82.2 million last year, surpassing the Street's $98.8 million view.
For Q2, the company forecasts a non-GAAP loss to be between $0.11 and $0.13 per share on revenue in the range of $101.8 million to $102.2 million.
This compares to consensus estimates for a profit of $0.02 per share on revenue of $102.0 million.
For 2022, the company raised its EPS guidance to $0.23 to $0.27 from its prior guidance of $0.22 to $0.26 per share.
Revenue expectations were moved to between $428.2 million to $432.8 million from $426 million to $432 million previously projected.
This compares to the consensus estimate for 2022 of $0.24 in earnings on $428.6 million in revenue.
The stock fell 2.3% in after-hours trade.
Price: 35, Change: -0.82, Percent Change: -2.29
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|